R
Richard Glynne
Researcher at Genomics Institute of the Novartis Research Foundation
Publications - 70
Citations - 6895
Richard Glynne is an academic researcher from Genomics Institute of the Novartis Research Foundation. The author has contributed to research in topics: Insulin & Mycobacterium tuberculosis. The author has an hindex of 37, co-authored 70 publications receiving 6087 citations. Previous affiliations of Richard Glynne include Novartis & Stanford University.
Papers
More filters
Journal ArticleDOI
Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing.
Laura Riva,Shuofeng Yuan,Xin Yin,Laura Martin-Sancho,Naoko Matsunaga,Lars Pache,Sebastian Burgstaller-Muehlbacher,Paul D. De Jesus,Peter Teriete,Mitchell V. Hull,Max W. Chang,Jasper Fuk-Woo Chan,Jianli Cao,Vincent Kwok-Man Poon,Kristina M. Herbert,Kuoyuan Cheng,Kuoyuan Cheng,Tu Trinh H. Nguyen,Andrey Rubanov,Yuan Pu,Courtney Nguyen,Angela Choi,Raveen Rathnasinghe,Michael Schotsaert,Lisa Miorin,Marion Dejosez,Thomas P. Zwaka,Ko Yung Sit,Luis Martinez-Sobrido,Wen-Chun Liu,Kris M. White,Mackenzie E. Chapman,Emma K. Lendy,Richard Glynne,Randy A. Albrecht,Eytan Ruppin,Andrew D. Mesecar,Jeffrey R Johnson,Christopher Benner,Ren Sun,Peter G. Schultz,Andrew I. Su,Adolfo García-Sastre,Arnab K. Chatterjee,Kwok-Yung Yuen,Sumit K. Chanda +45 more
TL;DR: A screen of the ReFRAME library of approximately 12,000 known drugs for antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) identified several candidate compounds with suitable activities and pharmacological profiles, which could potentially expedite the deployment of therapies for coronav virus disease 2019 (COVID-19).
Journal ArticleDOI
A proteasome-related gene between the two ABC transporter loci in the class II region of the human MHC.
TL;DR: A human gene with sequence homology to proteasome components is identified, and remarkably, this gene maps between the two putative peptide transporter genes.
Journal ArticleDOI
Targeting Plasmodium PI(4)K to eliminate malaria
Case W. McNamara,Marcus C. S. Lee,Chek Shik Lim,Siau Hoi Lim,Jason Roland,Oliver Simon,Bryan K. S. Yeung,Arnab K. Chatterjee,Susan McCormack,Micah J. Manary,Anne-Marie Zeeman,Koen J. Dechering,Tr Santha Kumar,Philipp P. Henrich,Kerstin Gagaring,Maureen Ibanez,Nobutaka Kato,Kelli Kuhen,Christoph Fischli,Advait Nagle,Matthias Rottmann,Matthias Rottmann,David Plouffe,Badry Bursulaya,Stephan Meister,Lucia E. Rameh,Joerg Trappe,Dorothea Haasen,Martijn Timmerman,Robert W. Sauerwein,Rossarin Suwanarusk,Bruce Russell,Bruce Russell,Laurent Rénia,François Nosten,David C. Tully,Clemens H. M. Kocken,Richard Glynne,Christophe Bodenreider,David A. Fidock,Thierry T. Diagana,Elizabeth A. Winzeler,Elizabeth A. Winzeler +42 more
TL;DR: It is shown that imidazopyrazines exert their effect through inhibitory interaction with the ATP-binding pocket of PI(4)K, altering the intracellular distribution of phosphatidylinositol-4-phosphate.
Journal ArticleDOI
Second proteasome-related gene in the human MHC class II region.
TL;DR: A second human proteasome-like gene, RING12, is described, immediately centromeric of the RING4 locus, which forms a tightly linked cluster of interferon-inducible genes within the MHC with an essential role in antigen processing.
Journal ArticleDOI
Imaging of Plasmodium Liver Stages to Drive Next-Generation Antimalarial Drug Discovery
Stephan Meister,David Plouffe,Kelli Kuhen,Ghislain M. C. Bonamy,Tao Wu,S. Whitney Barnes,Selina Bopp,Rachel Borboa,A. Taylor Bright,A. Taylor Bright,Jianwei Che,Steve Cohen,Neekesh V. Dharia,Kerstin Gagaring,Montip Gettayacamin,Perry Gordon,Todd Groessl,Nobutaka Kato,Marcus C. S. Lee,Case W. McNamara,David A. Fidock,Advait Nagle,Tae-gyu Nam,Wendy Richmond,Jason Roland,Matthias Rottmann,Matthias Rottmann,Bin Zhou,Patrick Froissard,Patrick Froissard,Richard Glynne,Dominique Mazier,Dominique Mazier,Jetsumon Sattabongkot,Peter G. Schultz,Tove Tuntland,John R. Walker,Yingyao Zhou,Arnab K. Chatterjee,Thierry T. Diagana,Elizabeth A. Winzeler,Elizabeth A. Winzeler +41 more
TL;DR: An imidazolopiperazine scaffold series was identified that was highly enriched among compounds active against Plasmodium liver stages and shows potent in vivo blood-stage therapeutic activity.